Melina Elpi Marmarelis, MD, discusses the efficacy of lazertinib and amivantamab-vmjw plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer.
Melina Elpi Marmarelis, MD, hematology, medical oncology, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the efficacy of lazertinib (Leclaza) and amivantamab-vmjw (Rybrevant) plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC).
The phase 1 CHRYSALIS-2 trial (NCT04077463) is examining the use of lazertinib as a single agent and in combination with amivantamab, with or without chemotherapy, for patients with advanced or metastatic EGFR mutations.
Findings presented at the 2022 World Conference on Lung Cancer showed that the combination of lazertinib and amivantamab plus carboplatin and pemetrexed elicited an overall response rate (ORR) of 50% in the overall population (n = 20), plus an ORR of 50% in 10 patients that had prior brain metastases, Marmarelis says. Compared with observed ORRs for chemotherapy alone or the combination of amivantamab and lazertinib without chemotherapy in this patient population, these responses were impressive, Marmarelis explains.
At the time of data cutoff with a median follow-up of about 7 months, 15 of 20 patients remained on treatment, Marmarelis continues. Though investigators are currently unable to estimate the median duration of response, data have pointed to patients are having durable responses, Marmarelis concludes.